BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16172607)

  • 1. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography.
    Liu T; Toriyabe Y; Berkman CE
    Protein Expr Purif; 2006 Oct; 49(2):251-5. PubMed ID: 16815035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of prostate-specific membrane antigen in the serum with a new antibody.
    Murphy GP; Tino WT; Holmes EH; Boynton AL; Erickson SJ; Bowes VA; Barren RJ; Tjoa BA; Misrock SL; Ragde H; Kenny GM
    Prostate; 1996 Apr; 28(4):266-71. PubMed ID: 8602402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.
    Moffatt S; Papasakelariou C; Wiehle S; Cristiano R
    Gene Ther; 2006 May; 13(9):761-72. PubMed ID: 16453011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive and antibody-induced internalization of prostate-specific membrane antigen.
    Liu H; Rajasekaran AK; Moy P; Xia Y; Kim S; Navarro V; Rahmati R; Bander NH
    Cancer Res; 1998 Sep; 58(18):4055-60. PubMed ID: 9751609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
    Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO
    Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
    Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
    J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody.
    Ikegami S; Yamakami K; Ono T; Sato M; Suzuki S; Yoshimura I; Asano T; Hayakawa M; Tadakuma T
    Hum Gene Ther; 2006 Oct; 17(10):997-1005. PubMed ID: 17032155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
    Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
    Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.